ResMed is a wide-moat medical devices company with a perfect Piotroski F-Score of 9 out of 9, 25% return on equity, and four consecutive earnings beats, currently experiencing a technical downtrend that creates an accumulation opportunity for investors with a 12-to-18 month horizon.
Thesis pillars
- Wide Moat Compounder Quality→Stable
- Perfect Earnings Beat Streak→Stable
- Technical Downtrend Accumulation Window↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Aug 13, 2026· older than 90 days
ResMed Inc. (RMD) Stock Analysis
Range Bound setup · Temporary headwind edge
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $240.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining.
ResMed makes cloud-connected CPAP and bilevel devices, masks, ventilators and diagnostics for sleep apnea and chronic respiratory disease, plus residential care software (Brightree, MEDIFOX DAN, MatrixCare) in a second segment. Products sell in more than 140 countries through... Read more
Hold if already holding. Not a fresh buy at $240.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: RSI 49 mid-range, Bollinger mid-band. Downgraded from BUY WAIT — price $240.51 vs the analyst target $238.59: -0.8% upside; No upside left. Score 5.9/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 84d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and SEC filing concern. Suitability: moderate.
About ResMed Inc.
About ResMed Inc.
ResMed sells cloud-connected CPAP devices, masks, ventilators and software for sleep apnea and chronic respiratory disease in more than 140 countries and employs approximately 11,370 people. Sales in Rest of World regions made up 37% of net revenues in fiscal 2026, up from 36% a year earlier, and the company manufactures substantially all of its products outside the United States. It reports two segments, Sleep and Breathing Health and Residential Care Software.
Sleep and Breathing Health covers CPAP and bilevel systems such as the AirCurve 11 series, masks and accessories, the NightOwl home sleep test, the myAir coaching app, and ventilation and high flow therapy for COPD, obesity hypoventilation and neuromuscular disease, sold through wholly owned subsidiaries and independent distributors to home medical equipment providers. The 2025 purchase of VirtuOx added a software-enabled independent diagnostic testing facility, and the June 2026 acquisition of Noctrix extended the clinical portfolio to restless legs syndrome. Residential Care Software, through Brightree, MEDIFOX DAN and MatrixCare, serves home medical equipment, home health, hospice, senior living and nursing providers; on June 30, 2026 the company agreed to sell the MatrixCare business for $490 million in cash, expected to close in the first quarter of fiscal 2027. Competitors named in the filing include Philips, which continues to operate in the U.S. under a consent decree after its product recall.
Show full overview
Substitution and payor pressure frame the risk. The 10-K says pharmaceutical treatments such as GLP-1 drugs approved for diabetes and weight loss may reduce obesity and could potentially lessen the severity or existence of obstructive sleep apnea, which might slow demand for devices. Consolidation among home medical equipment providers and payors may let buyers push for price concessions or volume reductions, and reimbursement changes could cut selling prices. In August 2026, the company disclosed via Form 8-K that it dismissed KPMG as its auditor on August 13, 2026 following a competitive review process, citing no disagreements or reportable events.
See also: Healthcare · Medical Instruments & Supplies
From ResMed Inc.'s most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated Nov 5, 2026Recent Developments — ResMed Inc.
Latest news
- NEWS ResMed Inc (RMD) Stock Up 5.9% and Still Undervalued -- GF Score: 99/100 - GuruFocus — GuruFocus Nov 5, 2026 positive
- NEWS Your RMD Deadline Is Coming. Here’s How to Decide Which ETF to Take It From - 24/7 Wall St. — 24/7 Wall St. Nov 4, 2026 neutral
- NEWS ResMed: A Quality Compounder, But Not Yet A Bargain (NYSE:RMD) - Seeking Alpha — Seeking Alpha Nov 3, 2026 neutral
- NEWS Unlocking Q1 Potential of ResMed (RMD): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS ResMed (RMD) Q3 earnings report preview: what to look for - TradingView — TradingView Oct 28, 2026 neutral
Latest item Nov 5, 2026 · Generated 2026-11-05T11:44:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMGeographicRest of World regions37%10-K Item 1A: 'Sales in Rest of World regions accounted for approximately 37% and 36% of our net revenues in the years ended June 30, 2026 and June 30, 2025, respectively.'
- HIGHGeographicmanufacturing outside the U.S.10-K Item 1A: 'We manufacture substantially all of our products outside the U.S. and sell a significant portion of our products outside the U.S.'
Material Events(8-K, last 90d)
- 2026-08-17Item 4.01HIGHDismissed KPMG LLP as independent auditor effective August 13, 2026; KPMG's reports for fiscal 2026 and 2025 had no adverse opinion, and there were no disagreements or reportable events. The Audit Committee chose a successor after a competitive review process (name not visible in the available text).SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $240.51, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining. Chart setup: RSI 49 mid-range, Bollinger mid-band. Downgraded from BUY WAIT — price $240.51 vs the analyst target $238.59: -0.8% upside; No upside left. Analyst target $238.59 reached (−0.8%), stop $214.94 (−11.9%), A.R:R -0.1:1. Score 5.9/10, moderate confidence.
Analyst target $238.59 reached (−0.8% from $240.51); no take-profit level is published. Analyst target $238.59 reached (−0.8%), stop $214.94 (−11.9%), A.R:R -0.1:1. Stop-loss: $214.94.
Concentration risk — Geographic: manufacturing outside the U.S.; Analyst target reached - limited upside remaining; Negative momentum.
ResMed Inc. trades at a P/E of 21.9 (forward 18.1). TrendMatrix value score: 5.4/10. Verdict: Hold.
27 analysts rate RMD, with a consensus score of 3.6/5. 17 analysts publish price targets averaging $265.
What does ResMed Inc. do?ResMed makes cloud-connected CPAP and bilevel devices, masks, ventilators and diagnostics for sleep apnea and chronic...
ResMed makes cloud-connected CPAP and bilevel devices, masks, ventilators and diagnostics for sleep apnea and chronic respiratory disease, plus residential care software (Brightree, MEDIFOX DAN, MatrixCare) in a second segment. Products sell in more than 140 countries through subsidiaries and independent distributors. Rest of World regions were 37% of fiscal 2026 net revenues, and substantially all products are manufactured outside the U.S.